Biome Australia (BIO) H2 2025 earnings summary

Executive summary

• Achieved first net profit after tax of $214,656 in FY25, marking a historic milestone since founding in 2018.

• Sales revenue reached $18.4 million, up 41.6% year-over-year, with June quarter sales exceeding $5 million.

• International sales grew 69% to $1.5 million, driven by strategic expansion and new distribution partnerships.

• Launched new brand and seven novel products, including the Activated Therapeutics practitioner-only range.

• Positioned as the number two probiotic brand in community pharmacy, with domestic sell-through up over 50%.

Financial highlights

• Full-year EBITDA (excluding share-based payments) was $931k, with sixth consecutive quarter of positive EBITDA.

• Gross profit reached $11.25 million; gross margin increased to 61.1%.

• Q4 FY25 was the strongest quarter, with sales revenue surpassing $5 million and a record $2.1 million in June.

• Annualized sales revenue run rate entering FY26 exceeded $20 million.

Outlook and guidance

• On track to achieve Vision 27 forecast of at least $75 million in cumulative sales for FY25-27.

• Strategic international deals expected to support further growth and scale in FY26.

• Forward-looking statements caution that actual results may differ materially from projections.